Recent advances in genetic engineering have enabled the delivery of clinical trials using patient T cells redirected to recognize tumor-associated antigens. The most dramatic results have been seen with T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19, a differentiation antigen expressed in B cells and B lineage malignancies. We propose, that antigen expression in non-malignant cells may contribute to the efficacy of T cell therapy by maintaining effector function and promoting memory. While CAR recognition is limited to cell surface structures, T cell receptors (TCR) can recognize intracellular proteins. This not only expands the range of tumor-associated self-antigens that are amenable for T cell therapy, but it also allows TCR targeting of the cancer mutagenome. We will highlight biological bottlenecks that potentially limit mutation-specific T cell therapy and may require high avidity TCR that are capable of activating effector function when the concentrations of mutant peptides are low.
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Abstract: Recent advances in genetic engineering have enabled the delivery of clinical trials using patient T cells redirected to recognize tumor-associated antigens. The most dramatic results have been seen with T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19, a differentiation antigen expressed in B cells and B lineage malignancies. We propose, that antigen expression in non-malignant cells may contribute to the efficacy of T cell therapy by maintaining effector function and promoting memory. While CAR recognition is limited to cell surface structures, T cell receptors (TCR) can recognize intracellular proteins. This not only expands the range of tumor-associated self-antigens that are amenable for T cell therapy, but it also allows TCR targeting of the cancer mutagenome. We will highlight biological bottlenecks that potentially limit mutation-specific T cell therapy and may require high avidity TCR that are capable of activating effector function when the concentrations of mutant peptides are low.
Unexpectedly, modified TCRs with artificially high affinities function poorly in response to low concentration of cognate peptide, but pose an increased safety risk as they may respond optimally to cross-reactive peptides. The recent gene editing tools, such as TALEN and CRIPSR, provide a platform to delete endogenous TCR and HLA genes, which removes allo-reactivity and decreases immunogenicity of third party T cells. This represents an important step towards generic off-the-shelf T cell products that may be used in the future for the treatment of large numbers of patients.
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 3 Engineering of T cell specificity: Rapid improvements of gene transfer technologies have provided a robust platform to redirect the specificity of primary T cells 1 . This has overcome a major obstacle for targeted T cell therapy, posed by the relatively low frequency of cancer-reactive T cells that are naturally present in patients, or that can be induced by vaccination. Retro and lenti-viral gene transfer platforms have been developed to achieve the expression of cancer-reactive T cell receptors (TCRs) and chimeric antigen receptors (CARs) in primary T cells, generating therapeutic cellular products with a high level of tumor specificity 2 . There is now the opportunity to direct the therapeutic power of T cell therapy towards defined cancer antigens and thus avoid the toxicity of donor lymphocyte infusion which is caused by the allo-reactivity of the polyclonal TCR repertoire of infused T cells.
TCRs or CARs to target malignant cells: TCRs recognize peptide
fragments presented by HLA molecules 3 . An evolutionary advantage of this mode of antigen recognition enables T cells to recognize and attack virus infected cells, even when viral proteins are 'hidden' inside cells and absent from the surface 4 . Similarly, this mode of recognition renders intracellular cancer proteins susceptible for targeted attack by TCRs ( Fig. 1 ). For example, most cancer testis antigens are not expressed on the surface of tumor cells but are nevertheless efficiently targeted by TCRs, but not by CARs 5 .
Similarly, intracellular proteins such as Wilms Tumor Antigen-1 and minor histocompatibility antigens have been validated in preclinical experiments as attractive targets for the treatment of hematological malignancies [6] [7] [8] [9] . TCR The TCR recognition is focused on short linear peptide epitopes presented by HLA class I molecules (9-10 amino acid peptides) and HLA class II molecules (15-18 amino acids) 10, 11 . While some of these peptide residues mediate HLA binding, other residues interact primarily with the complementary determining region 3 (CDR 3) of the TCR, providing appropriate engagement required for T cell activation 12 . Both HLA binding and TCR interaction can be exquisitely sensitive to single amino acid substitutions, which is an important consideration for cancer immunology. While patient T cells are tolerant to self-peptides derived from self-proteins, point mutations in tumor cells resulting in single amino acid changes, can elicit robust T cell responses [13] [14] [15] [16] [17] [18] [19] [20] .
There are two mechanisms whereby point mutations can generate immunogenic epitopes to which patient T cells are not tolerant. Firstly, mutations may generate novel TCR contact residues and thus produce immunogenic neo-epitopes, or, alternatively, they may create novel HLA binding residues resulting in the presentation of peptides in tumor cells that are absent in normal tissues. Due to recognition of linear peptide sequences, TCRs can potentially target the mutational landscape associated with cancer development, although, as discussed below, cellular mechanisms of peptide production and transport impose considerable limitations. In contrast to TCRs, point mutations largely escape antibody recognition and thus CAR targeting, because the vast majority of mutated proteins are intracellular and because antibodies are less effective in the specific recognition of point mutations in otherwise unaltered self-proteins. 36 . It is not known from the human studies whether the continued elimination of B cells might trigger the sustained T cell persistence. We would like to speculate that the interaction with normal B cells, which can provide T cell co-stimulation and function as efficient antigen-presenting cells 37 , might contribute to promoting the expansion and maintenance of the therapeutic T cells in vivo ( Fig. 2 ). Similar For personal use only. on October 4, 2017. by guest www.bloodjournal.org From to CD19 targeted immunotherapy, successful immunotherapy of melanoma is associated with vitiligo caused by the T cell recognition of tissue-specific antigens in normal melanocytes 38, 39 . Interestingly, studies in murine models have indeed provided evidence that the interaction with melanocytes provided T cell stimulation and contributed to sustaining the memory potential of the therapeutic T cells 40 .
However, the expression of self-antigens in tissues and cell types that are unable to provide T cell co-stimulation may result in the induction of anergy For TCR gene therapy, it is therefore advisable to consider the expression pattern of therapeutic target antigens not only in the context of possible toxicity, but to also take into account the impact on the modulation of T cell function. We suggest that it may be desirable for tumor-associated selfantigens to be expressed in normal cells that are capable of T cell stimulation and whose loss, as a consequence of T cell attack, does not cause untreatable toxicity. The observation that antigen expression in the hematopoietic compartment can promote T cell function suggests that lineage-specific antigens may be good targets for the treatment of For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 8 hematological malignancies. The haplo-identical transplantation protocol that was recently used for adoptive transfer of non-engineered T cells could potentially provide an excellent platform to achieve the selective TCR targeting of leukemia 42 . For example, it would be possible to engineer donor T cells with a TCR specific for a hematopoietic-specific antigen presented by an HLA class I allele that is expressed by the patient but not by the donor. In this case, the engineered T cells would selectively attack patient leukemia and hematopoietic cells, but spare donor cells that lack the HLA molecule required for the recognition of the hematopoietic antigen.
Achieving unique tumor-specificity: Chronic myeloid leukemia is characterized by the BCR/ABL translocations that often produces the same mutant protein in patients 43 . The targeting of this mutant protein with small molecule inhibitors such as Imatinib was a first example of a highly diseasespecific therapy resulting in CML control in the majority of patients. The BCR/ABL fusion protein also contains linear peptide sequences that are unique to CML and absent in all non-malignant cells. Despite substantial efforts to exploit fusion peptides for vaccination and to identify fusion-specific T cell responses, the clinical results have been disappointing and clear evidence of fusion-specific T cells capable of recognizing and killing CML remains absent 44 . This is puzzling, considering that mutation-specific responses by both CD4+ helper T cells and CD8+ cytotoxic T cells have now been clearly identified in patients with melanoma and gastrointestinal cancer 13, 16, 19, 20 . Why is it, therefore, that BCR/ABL 'escapes' T cell immunity when other mutations trigger robust T cell responses? There are a number of requirements that a peptide has to meet to function as an epitope for T cell attack (Fig. 1) . The proteasome has to cleave the protein to generate the appropriate peptide, which then has to interact productively with the TAP complex for transport into the ER, and inside the ER, peptides have to display sufficient binding affinity for HLA molecules to compete successfully with the large number of normal self-peptides generated from the set of 10,000-15,000 proteins that are expressed in human cells 45 . The following considerations illustrate that the majority of cancer mutations are predicted to be invisible to immune recognition. Although tumors such as lung cancer and melanoma harbor approximately 30,000 somatic mutations, the protein encoding exome represents 1% of the entire genome, indicating that approximately 300 mutations occur in protein coding sequences. Of the 300 DNA alterations, only the non-synonymous mutations and frame shifts will change amino acids and create an altered protein. Proteasome mediated cleavage of the protein needs to release the mutation containing peptides with the correct C-terminal residues required for HLA binding (Fig. 1) 46 . This, however, is often not the case and it has been demonstrated that proteasome cleavage can instead destroy TCR recognized peptide epitopes 47, 48 . The efficiency of peptide transport from the cytosol into the ER is the next rate- An alternative strategy to enhance TCR expression is the provision of additional CD3 molecules in engineered T cells. We have shown that the transfer of TCR and CD3 genes into primary T cells enhanced TCR expression and improved recognition of low concentration of antigen, which resulted in augmented tumor protection in vivo 59 . However, additional CD3 also leads to enhanced expression of endogenous and mis-paired TCR, thus increasing the risk of potential toxicity. The most effective strategy to prevent this risk is the disruption of endogenous TCR genes using zinc finger nucleases, TALENs or CRISPR-Cas9 technologies 60 . Altering TCR affinity is another strategy that has been used to achieve T cell stimulation by low antigen concentration. Unexpectedly, experiments have shown that high affinities that increase the TCR binding to HLA-peptide from the 'physiological' half-life of seconds into the range of minutes and hours, results in impaired ability to trigger T cell stimulation when peptide concentration is low 61 . As a consequence, T cells expressing modified TCRs with affinities similar to that of antibodies, are efficiently stimulated by high doses of cognate peptide, but fail to respond to low dose peptide ( Fig. 3) . At low dose of cognate peptide, one HLA/peptide complex needs to stimulate multiple TCR by a mechanism of serial triggering, which is disrupted when the half-life of TCR binding to HLA-peptide is too long 62 . Therefore, artificially high affinity not only impairs response to low concentration of cognate peptide, but it also enhances the risk of optimal triggering by cross-reactive peptides (Fig. 3 ). Compared to the binding of cognate antigen, cross-reactivity usually occurs at lower affinity and shorter half-life, and may therefore fall into the optimal range for serial triggering required for activation at low peptide concentration. In other words, artificially affinity matured TCR may be more effective in stimulating T cell responses against cross-reactive peptides compared with cognate peptides. This might have contributed to the fatal toxicities that have been seen with an affinity matured MAGE-3A TCR that cross-reacted against MAGE-A12 in the brain and against Titin expressed in heart tissue 63, 64 .
TCR-transduced CD4+ and CD8+ T cells:
There is increasing evidence for a key role of CD4+ T cells in cancer immunity. Data from melanoma trials have TCR engineering offers the opportunity to transfer HLA class I-restricted
TCRs into CD4+ T cells, thus redirecting their specificity against the same target epitopes that are normally recognized by CD8+ T cells 68, 69 .
Consequently, activation of CD4+ T cell function is no longer dependent on
antigen-presentation by HLA class II, which is frequently absent in tumor cells.
A possible disadvantage of this strategy is that HLA class I is widely expressed in most tissues, thus extending possible toxicities of therapy with redirected CD4+ T cells, or impairing their functional potential as a consequence of interaction with cells and tissues that can induce T cell anergy (Fig. 2) . Optimal functional capability of engineered T cells may be achievable by the targeted disruption of genes involved in the inhibition of T cell function and by providing transgenes that encode immune enhancing molecules (Fig. 4) . The delivery of immune stimulatory cytokines is another strategy that has been used to enhance the anti-tumor effect of engineered T cells. The most studied cytokine is IL12, which was controlled by an NFAT promoter to achieve IL12 production following TCR engagement 72 . Such TCR controlled expression can potentially overcome the substantial toxicity that is seen when IL12 is given systemically. However, recent results of a clinical trial revealed toxic side effects of engineered T cells expressing IL12 under the control of the NFAT promoter 72 . Thus, the experience to date has shown that IL12 is effective in enhancing anti-tumor activity of adoptive T cell transfer, but Note that protesasome may not cleave at the apprpriate position and that the mutation containing peptide may not be transported by TAP or fail to bind to HLA.
Genome editing to modulate T cell function:

Figure 2: Interaction of tumor-reactive T cells with normal tissues.
The right side illustrates that cells in normal tissues may be able to provide costimulation, which results in T cell activation and expansion. The left side illustrates that the interaction with cells that do not provide co-stimulation might induce a state of 'sleepy' T cell anergy.
Figure 3: Risk of cross-reactivity by affinity matured TCR. Engineered
TCRs with artificially high affinity require high peptide concentration to stimulate T cell responses (black titration curve indicates stimulation with cognate peptide). This is due to the long half-life of binding, which prevents sequential engagement of several TCRs with a single HLA/peptide ligand.
Cross-reactive peptides are expected bind the same TCR with reduced affinity and binding half-life, and may fall into the optimal range for sequential TCR engagement that is required for T cell activation at low peptide concentration.
Hence, the red titration curve indicates that the affinity matured TCR is triggered by lower concentration of cross-reactive peptide compared to cognate peptide (black curve). 
